The GCDH Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Burkitt lymphoma Raji B lymphocyte line. This product comprises a heterogeneous pool of cells harboring targeted disruption of the GCDH gene, enabling loss-of-function studies in a well-characterized lymphoblastoid background. The polyclonal format provides a robust model for investigating GCDH-dependent metabolic processes without requiring single-cell clonal isolation.
The Raji cell line is an Epstein-Barr virus (EBV)-positive B lymphocyte model established from a Burkitt lymphoma patient. These lymphoblast-like cells are extensively utilized in cancer biology, immunology, and hematological malignancy research due to their rapid proliferation, stable karyotype, and well-defined signaling networks. The Raji background offers a relevant context for examining the intersection of B cell physiology and metabolic enzyme function.
GCDH encodes glutaryl-CoA dehydrogenase, a mitochondrial matrix enzyme that catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO?, employing flavin adenine dinucleotide (FAD) as a cofactor. Electrons derived from this reaction are transferred to the electron transfer flavoprotein (ETF), which subsequently feeds into the mitochondrial respiratory chain via ETF dehydrogenase. GCDH activity is regulated by substrate availability and is transcriptionally modulated by peroxisome proliferator-activated receptor alpha (PPAR??) and its coactivator PGC-1??. Downstream, the product crotonyl-CoA can be further metabolized to acetyl-CoA through crotonase and ??-oxidation, linking amino acid catabolism to central energy pathways. Key pathway components include glutaryl-CoA, crotonyl-CoA, acetyl-CoA, ETF, and ETF dehydrogenase.
In the Raji B cell lymphoma context, disruption of GCDH recapitulates key metabolic signatures of glutaric acidemia type I, an inherited organic aciduria characterized by accumulation of glutaryl-CoA and its neurotoxic derivatives. The loss of glutaryl-CoA dehydrogenase activity impairs lysine and tryptophan degradation, potentially compromising mitochondrial energy production and elevating reactive oxygen species (ROS) levels. This knockout model enables dissection of how GCDH deficiency affects B lymphocyte metabolism, survival, and stress responses, offering insights into metabolic vulnerabilities in lymphoid malignancies.
Researchers can utilize this polyclonal knockout pool to study glutaric acidemia type I pathobiology, investigate lysine and tryptophan catabolism, and perform drug screening for organic acidurias. The model facilitates mitochondrial function assays via Seahorse respirometry and ROS measurement. GCDH knockout validation can be achieved through Western blotting, RT-qPCR, and Sanger sequencing, while glutaryl-CoA levels are quantifiable by LC-MS. Proliferation assays further characterize the metabolic impact on B lymphoma cells. For further information, please contact Ascent Research.
